Valuation: Verastem, Inc.

Market Cap 40Cr 35Cr 32Cr 30Cr 56Cr 3.77TCr 57Cr 381.39Cr 148.26Cr 1.85TCr 148.43Cr 145.24Cr 6.38TCr P/E 2026 *
-2.85x
P/E 2027 * -4.03x
Enterprise Value 23Cr 20Cr 19Cr 17Cr 33Cr 2.19TCr 33Cr 222.25Cr 86Cr 1.08TCr 86Cr 85Cr 3.72TCr EV / Sales 2026 *
2.25x
EV / Sales 2027 * 1.04x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+9.76%
1 week+19.05%
Current month+17.80%
1 month+24.31%
3 months-20.07%
6 months-37.76%
Current year-41.71%
1 week 3.74
Extreme 3.745
4.57
1 month 3.43
Extreme 3.43
4.57
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
47.46
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06Sell

Chief Executive Officer

-20,871 0.0339%
22/06Sell

Chief Financial Officer

-4,089 0.0066%
21/05Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+9.76%+19.05%-6.25%-41.94% 40Cr
+0.68%+5.92%+80.45%+137.78% 5.91TCr
+2.32%+5.03%+75.51%+94.88% 5.52TCr
+3.86%+6.93%-11.32%-9.53% 2.47TCr
+4.30%+7.95%+14.11%+437.83% 2.42TCr
+4.74%+13.68%+45.58%-1.42% 1.97TCr
-0.29%+9.78%+44.62%-27.94% 1.76TCr
0.00%+20.78%+178.93%+360.74% 1.62TCr
+3.50%+1.97%+21.02%+191.95% 1.4TCr
+6.72%+19.38%+42.82% - 1.48TCr
Average +3.56%+10.75%+48.55%+126.93% 2.46TCr
Weighted average by Cap. +2.47%+6.51%+58.95%+137.40%

Financials

2026 *2027 *
Net sales 10Cr 8.94Cr 8.22Cr 7.66Cr 15Cr 973.96Cr 15Cr 99Cr 38Cr 478.75Cr 38Cr 38Cr 1.65TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.7TCr 26Cr 172.43Cr 67Cr 836.75Cr 67Cr 66Cr 2.88TCr
Net income -17Cr -15Cr -13Cr -12Cr -24Cr -1.58TCr -24Cr -160.3Cr -62Cr -777.88Cr -62Cr -61Cr -2.68TCr -14Cr -12Cr -11Cr -11Cr -20Cr -1.35TCr -20Cr -136.55Cr -53Cr -662.63Cr -53Cr -52Cr -2.28TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -24Cr -159.14Cr -62Cr -772.25Cr -62Cr -61Cr -2.66TCr -21Cr -18Cr -17Cr -16Cr -30Cr -2TCr -30Cr -202.16Cr -79Cr -980.99Cr -79Cr -77Cr -3.38TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
02/26/02 $4.500 +9.76% 29,67,738
01/26/01 $4.100 +7.33% 21,86,504
30/26/30 $3.820 0.00% 34,45,491
29/26/29 $3.820 +1.06% 26,84,221
26/26/26 $3.780 +9.57% 80,27,834
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.500USD
Average target price
15.12USD
Spread / Average Target
+236.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock